Patents by Inventor Gopalan Raghunathan

Gopalan Raghunathan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-TIGIT ANTIBODIES
    Publication number: 20160355589
    Abstract: The present invention relates to anti-TIGIT antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Application
    Filed: August 17, 2015
    Publication date: December 8, 2016
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Sybil M. G. Williams, Drake LaFace, Laurence Fayadat-Dilman, Gopalan Raghunathan, Linda Liang, Wolfgang Seghezzi
  • Human Oncostatin M Antibodies and Methods of Use
    Publication number: 20160009798
    Abstract: Antibodies and compositions capable of neutralizing oncostatin M biological functions are useful in treating diseases and disorders associated with oncostatin M, such as osteoarthritis and idiopathic pulmonary fibrosis.
    Type: Application
    Filed: September 30, 2015
    Publication date: January 14, 2016
    Inventors: Juan Carlos Almagro, William DuBell, Johann Fransson, Jose Pardinas, Gopalan Raghunathan
  • Human oncostatin M antibodies
    Patent number: 9163083
    Abstract: Antibodies and compositions capable of neutralizing oncostatin M biological functions are useful in treating diseases and disorders associated with oncostatin M, such as osteoarthritis and idiopathic pulmonary fibrosis.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: October 20, 2015
    Inventors: Juan Carlos Almagro, William DuBell, Johan Fransson, Jose Pardinas, Gopalan Raghunathan
  • CH2 domain template molecules derived from rational grafting of donor loops onto CH2 scaffolds
    Patent number: 9156917
    Abstract: Novel CH2 domain template molecules wherein donor loops from a database of domains are transferred to a CH2 domain scaffold. At least one or up to three loops from a donor are transferred to the CH2 domain. The donor loops may be chosen based on length, e.g., the donor loop may have a length that is similar to that of a structural loop in the CH2 domain scaffold.
    Type: Grant
    Filed: February 10, 2012
    Date of Patent: October 13, 2015
    Assignee: RESEARCH CORPORATION TECHNOLOGIES, INC.
    Inventors: David Bramhill, Gopalan Raghunathan
  • Human tissue factor antibody and uses thereof
    Patent number: 8999333
    Abstract: The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.
    Type: Grant
    Filed: March 31, 2014
    Date of Patent: April 7, 2015
    Assignee: Janssen Biotech, Inc.
    Inventors: Juan Carlos Almagro, Glenn Mark Anderson, Ellen Chi, Christian Martinez, Gopalan Raghunathan, Ronald Swanson, Alexey Teplyakov, Kam-Fai Tse, Sheng-Jiun Wu, Hong Mimi Zhou
  • Human tissue factor antibody and uses thereof
    Patent number: 8951525
    Abstract: The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: February 10, 2015
    Assignee: Janssen Biotech, Inc.
    Inventors: Juan Carlos Almagro, Glenn Mark Anderson, Ellen Chi, Christian Martinez, Gopalan Raghunathan, Ronald Swanson, Alexey Teplyakov, Kam-Fai Tse, Sheng-Jiun Wu, Hong Mimi Zhou
  • TOLL LIKE RECEPTOR 3 ANTAGONISTS, METHODS AND USES
    Publication number: 20140255388
    Abstract: Toll Like Receptor 3 (TLR3) antagonists, polynucleotides encoding TLR3 antagonists or fragments, and methods of making and using the foregoing are disclosed.
    Type: Application
    Filed: March 13, 2013
    Publication date: September 11, 2014
    Inventors: Jill M. Carton, Shizhong Chen, Mark Cunningham, Anuk Das, Karen Duffy, Jill Giles-Komar, Theresa Goletz, David Knight, Roberta Lamb, Lamine Mbow, Gopalan Raghunathan, Lani San Mateo, Robert Sarisky, Nicole Stowell, Raymond Sweet, Shanrong Zhao
  • HUMAN TISSUE FACTOR ANTIBODY AND USES THEREOF
    Publication number: 20140234304
    Abstract: The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.
    Type: Application
    Filed: March 31, 2014
    Publication date: August 21, 2014
    Applicant: Janssen Biotech, Inc.
    Inventors: Juan Carlos ALMAGRO, Glenn Mark Anderson, Ellen Chi, Christian Martinez, Gopalan Raghunathan, Ronald Swanson, Alexey Teplyakov, Kam-Fai Tse, Sheng-Jiun Wu, Hong Mimi Zhou
  • Methods for use in human-adapting monoclonal antibodies
    Patent number: 8748356
    Abstract: Methods useful for human adapting non-human monoclonal antibodies are disclosed. The methods select candidate human antibody framework sequences from a database of human germline genes or human sequences with somatic mutations.
    Type: Grant
    Filed: October 19, 2007
    Date of Patent: June 10, 2014
    Assignee: Janssen Biotech, Inc.
    Inventor: Gopalan Raghunathan
  • Human tissue factor antibody and uses thereof
    Patent number: 8722044
    Abstract: The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: May 13, 2014
    Assignee: Janssen Biotech, Inc.
    Inventors: Juan Carlos Almagro, Glenn Mark Anderson, Ellen Chi, Christian Martinez, Gopalan Raghunathan, Ronald Swanson, Alexey Teplyakov, Kam-Fai Tse, Sheng-Jiun Wu, Hong Mimi Zhou
  • Human Oncostatin M Antibodies and Methods of Use
    Publication number: 20140099315
    Abstract: Antibodies and compositions capable of neutralizing oncostatin M biological functions are useful in treating diseases and disorders associated with oncostatin M, such as osteoarthritis and idiopathic pulmonary fibrosis.
    Type: Application
    Filed: December 12, 2013
    Publication date: April 10, 2014
    Inventors: Juan Carlos Almagro, William DuBell, Johan Fransson, Jose Pardinas, Gopalan Raghunathan
  • Methods of affinity maturing antibodies
    Patent number: 8580714
    Abstract: The invention relates to methods of affinity maturing antibodies.
    Type: Grant
    Filed: October 14, 2010
    Date of Patent: November 12, 2013
    Assignee: Janssen Biotech, Inc.
    Inventors: Juan Carlos Almagro, Johan Fransson, Gopalan Raghunathan
  • Human Tissue Factor Antibody and Uses Thereof
    Publication number: 20130189250
    Abstract: The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.
    Type: Application
    Filed: March 14, 2013
    Publication date: July 25, 2013
    Applicant: JANSSEN BIOTECH, INC.
    Inventors: Juan Carlos Almagro, Glenn Mark Anderson, Ellen Chi, Christian Martinez, Gopalan Raghunathan, Ronald Swanson, Alexey Teplyakov, Kam-Fai Tse, Sheng-Jiun Wu, Hong Mimi Zhou
  • Engineered anti-IL-13 antibodies, compositions, methods and uses
    Patent number: 8399630
    Abstract: The present invention relates to engineered antibodies immuno specific for human interleukin-13 (IL-13) protein or fragment thereof, as well as methods of making and using thereof, including therapeutic indications.
    Type: Grant
    Filed: August 11, 2009
    Date of Patent: March 19, 2013
    Assignee: Centocor Ortho Biotech Inc.
    Inventors: Ronald V. Swanson, Ellen Chi, Gopalan Raghunathan, Shanrong Zhao, Johan Fransson, Wendy Cordier, Hong Mimi Zhou, Juan C. Almagro, Linus Hyun, Jill Giles-Komar, Karyn T. O'Neil, Jill M. Carton, Alexey V. Teplyakov, Yiqing Feng
  • Engineered anti-IL-13 antibodies, compositions, methods and uses
    Patent number: 8323646
    Abstract: The present invention relates to engineered antibodies immunospecific for human interleukin-13 (IL-13) protein or fragment thereof, as well as methods of making and using thereof, including therapeutic indications.
    Type: Grant
    Filed: August 12, 2009
    Date of Patent: December 4, 2012
    Assignee: Centocor Ortho Biotech Inc.
    Inventors: Ronald V. Swanson, Ellen Chi, Gopalan Raghunathan, Shanrong Zhao, Johan Fransson, Wendy Cordier, Hong Mimi Zhou, Juan C. Almagro, Linus Hyun, Jill Giles-Komar, Karyn T. O'Neil, Jill M. Carton, Alexey V. Teplyakov, Yiging Feng
  • Human Tissue Factor Antibody and Uses Thereof
    Publication number: 20120237528
    Abstract: The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.
    Type: Application
    Filed: February 17, 2012
    Publication date: September 20, 2012
    Inventors: Juan Carlos Almagro, Glenn Mark Anderson, Ellen Chi, Christian Martinez, Gopalan Raghunathan, Ronald Swanson, Alexey Teplyakov, Kam-Fai Tse, Sheng-Jiun Wu, Hong Mimi Zhou
  • CH2 Domain Template Molecules Derived From Rational Grafting Of Donor Loops Onto CH2 Scaffolds
    Publication number: 20120230981
    Abstract: Novel CH2 domain template molecules wherein donor loops from a database of domains are transferred to a CH2 domain scaffold. At least one or up to three loops from a donor are transferred to the CH2 domain. The donor loops may be chosen based on length, e.g., the donor loop may have a length that is similar to that of a structural loop in the CH2 domain scaffold.
    Type: Application
    Filed: February 10, 2012
    Publication date: September 13, 2012
    Inventors: David Bramhill, Gopalan Raghunathan
  • Toll Like Receptor 3 Antagonists, Methods and Uses
    Publication number: 20120189643
    Abstract: Toll Like Receptor 3 (TLR3) antagonists, polynucleotides encoding TLR3 antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.
    Type: Application
    Filed: March 5, 2012
    Publication date: July 26, 2012
    Inventors: Jill M. Carton, Shizhong Chen, Mark Cunningham, Anuk Das, Karen Duffy, Jill M. Giles-Komar, Theresa J. Goletz, David M. Knight, Roberta Lamb, Mouhamadou L. Mbow, Kristen Picha, Gopalan Raghunathan, Lani San Mateo, Robert T. Sarisky, Vedrana Stojanovic-Susulic, Nicole Stowell, Raymond Sweet, Shanrong Zhao
  • Toll like receptor 3 antagonists, methods and uses
    Patent number: 8153583
    Abstract: Toll Like Receptor 3 (TLR3) antagonists, polynucleotides encoding TLR3 antagonists, and methods of making and using the foregoing are disclosed.
    Type: Grant
    Filed: November 30, 2005
    Date of Patent: April 10, 2012
    Inventors: Jill M. Carton, Shizhong Chen, Mark Cunningham, Anuk Das, Karen Duffy, Jill M. Giles-Komar, Theresa J. Goletz, David M. Knight, Roberta Lamb, Mouhamadou L. Mbow, Kristen Picha, Gopalan Raghunathan, Lani San Mateo, Robert T. Sarisky, Vedrana Stojanovic-Susulic, Nicole Stowell, Raymond Sweet, Shanrong Zhao
  • ENGINEERED ANTI-IL-13 ANTIBODIES, COMPOSITIONS, METHODS AND USES
    Publication number: 20120045438
    Abstract: The present invention relates to engineered antibodies immuno specific for human interleukin-13 (IL-13) protein or fragment thereof, as well as methods of making and using thereof, including therapeutic indications.
    Type: Application
    Filed: August 11, 2009
    Publication date: February 23, 2012
    Inventors: Ronald V. Swanson, Ellen Chi, Gopalan Raghunathan, Shanrong Zhao, Johan Fransson, Wendy Cordier, Hong Mimi Zhou, Juan C. Almagro, Linus Hyun, Jill Giles-Komar, Karyn T. O'Neil, Jill M. Carton, Alexey V. Teplyakov, Yiqing Feng